Rohit Gunan Ganju

Rohit Gunan Ganju

Auto-generated profile, based on publicly available information

Rohit Gunan Ganju

Department of Radiation Oncology, The University of Kansas Cancer Center, Kansas City, KS

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
RGRohit G. Ganju
Rohit G. Ganju
RMRyan Morse
Ryan Morse
AHAndrew Hoover
Andrew Hoover
MTMindi TenNapel
Mindi TenNapel
CLChristopher E. Lominska
Christopher E. Lominska

1 May 2021 in Clinical Lung Cancer
Verified
Journal Article
Closed access
SSSumit Sood
Sumit Sood
RGRohit Ganju
Rohit Ganju
XSXinglei Shen
Xinglei Shen
MNMindi Ten Napel
Mindi Ten Napel
FWFen Wang
Fen Wang

9 January 2018 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
RGRohit Gunan Ganju
Rohit Gunan Ganju
MTMindi TenNapel
Mindi TenNapel
NMNicholas Mahan
Nicholas Mahan
AZAmir Zahra
Amir Zahra
XSXinglei Shen
Xinglei Shen
Background. There is little data regarding the effectiveness of palliative radiation with conventional fractionation for metastatic renal cell carcinoma (RCC), which has been described as radioresistant. We conducted a retrospective analysis of patients with metastatic bony disease from RCC treated with radiation therapy at our institution. Methods. Forty patients with histologically confirmed RCC with a total of 53 treatment courses were included. Pain response after radiotherapy was recorded and freedom from progression was generated using posttreatment radiographs. Patient data was analyzed to assess influence on local control. Results. Patients had a median age of 63. Median follow-up was 9.3 months. The most common radiation dose was 30 Gy in 10 fractions. Pain control after radiotherapy was achieved in 73.6% of patients. Increasing age was associated with nonresponse at the initial pain assessment post-RT (p=0.02). In lesions with initial pain response, nonclear cell histology was associated with increased pain recurrence (p=0.01) and a shorter duration to pain recurrence (p=0.01). Radiographic control at 1 year was 62%. Conclusions. Pain response and control rates for osseous metastatic disease in RCC are comparable to other histologies when treated with conventional fractionation. These appear to be inferior to reported control rates from stereotactic treatments.

1 September 2019 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
PDF file
RGR.G. Ganju
R.G. Ganju
RMRyan T Morse
Ryan T Morse
MTM.J. Tennapel
M.J. Tennapel
AHA. Hoover
A. Hoover
KKK. Kakarala
K. Kakarala
CLC.E. Lominska
C.E. Lominska
Sarcopenia (decrease in skeletal muscle) is common in head and neck cancer patients and predicts poor prognosis in patients with p16-negative disease. Its impact in patients with p16-positive oropharynx cancers is unknown. Objective measures of sarcopenia include skeletal muscle index (SMI), skeletal muscle density (SMD), and skeletal muscle gauge (SMG), a novel measure which incorporates both SMI and SMD. We reviewed our institutional experience of p16-positive oropharynx cancer patients receiving concurrent chemoradiation and assessed outcomes with respect to skeletal muscle measures.